China healthcare

Hansoh Pharma vies for IPO attention amid biotech frenzy

The Jiangsu-based generic drug maker has started to bookbuild for a $1 billion IPO in Hong Kong, hoping to grab attention while the local exchange is focused on biotech firms.

Hansoh Pharmaceutical Group launched on Thursday Hong Kong’s second-largest initial public offering this year, looking for as much as HK$7.8 billion $1 billion as the Chinese generic drug manufacturer tries to draw investor attention away from a focus on biotech companies.

Hansoh’s Reg S144A deal features 551.3 million new shares, equivalent to 9.7% of the company’s enlarged share capital, and a greenshoe option of 82.6 million shares. The shares are being offered at HK$13.06 to HK$14.26 each, according to a deal termsheet.

Around 93% of the shares will be offered to institutional investors, while the rest will be offered to the public, subject...

¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team subscription (2-5 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team subscription (2-5 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222